Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | NOTCH1 | P46531 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27403170 | 0.92 | GPR119 (0.46) | FPR2USP30GPR119NOTCH1KDM4E | |
| SCHEMBL27402508 | 0.88 | GPR119 (0.54) | FPR2USP30GPR119KDM4EPKM | |
| SCHEMBL27402600 | 0.88 | USP30 (0.45) | FPR2USP30GPR119KDM4EPKM | |
| SCHEMBL34467038 | 0.85 | FPR2 (0.45) | FPR2USP30GPR119KDM4EPKM | |
| SCHEMBL34467020 | 0.84 | USP30 (0.42) | FPR2USP30GPR119NOTCH1KDM4E | |
| SCHEMBL27349340 | 0.84 | USP30 (0.42) | FPR2USP30GPR119NOTCH1KDM4E | |
| SCHEMBL27401969 | 0.84 | USP30 (0.43) | FPR2USP30GPR119NOTCH1DRD2 | |
| SCHEMBL27349454 | 0.80 | GPR119 (0.46) | USP30GPR119KDM4EPKMTGFBR1 | |
| SCHEMBL34466418 | 0.80 | GPR119 (0.43) | USP30GPR119DRD2MEN1KMT2A | |
| SCHEMBL34466417 | 0.80 | ALOX5AP (0.39) | FPR2USP30GPR119DRD2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2026-04-23 | — | — | US | disclosed |
| WO-2024073871-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023245327-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | GHSR, GSPT1, GLRA1 | FPR2 1681/4885USP30 1623/4885GPR119 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.